Millennium Management’s Theriva Biologics TOVX Stock Holding History

Millennium Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-537	Closed	-$38K	–	7508
2022 Q1	$38K	Buy	+537	New	+$36.6K	﹤0.01%	6475
2018 Q3	–	Sell	-23	Closed	-$48K	–	4278
2018 Q2	$48K	Sell	23 -31	-57%	-$71.2K	﹤0.01%	3706
2018 Q1	$151K	Sell	54 -38	-41%	-$145K	﹤0.01%	3425
2017 Q4	$410K	Sell	92 -32	-26%	-$200K	﹤0.01%	3193
2017 Q3	$1.01M	Sell	124 -23	-16%	-$133K	﹤0.01%	2505
2017 Q2	$729K	Buy	147 +105	+250%	+$523K	﹤0.01%	2614
2017 Q1	$231K	Sell	42 -44	-51%	-$307K	﹤0.01%	3153
2016 Q4	$576K	Buy	+86	New	+$883K	﹤0.01%	2613
2016 Q3	–	Sell	-6	Closed	-$92K	–	3609
2016 Q2	$92K	Sell	6 -8	-57%	-$151K	﹤0.01%	3031
2016 Q1	$285K	Buy	14 +7	+100%	+$105K	﹤0.01%	2792
2015 Q4	$145K	Buy	7 +4	+133%	+$84.6K	﹤0.01%	3187
2015 Q3	$65K	Sell	3 -1	-25%	-$24.6K	﹤0.01%	3320
2015 Q2	$95K	Sell	4 -1	-20%	-$20.1K	﹤0.01%	3175
2015 Q1	$94K	Buy	+5	New	+$89.3K	﹤0.01%	3412

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management's TOVX Position: Q2 2022 in Review

Millennium Management sold out of Theriva Biologics (TOVX) in Q2 2022, closing a stake of 537 shares — an estimated $38K sold.

Millennium Management first reported a position in TOVX in Q1 2015 and held it in 14 quarters. The position peaked at $1.01M in Q3 2017. 30 funds tracked by Wall St. Rank hold TOVX as of Q2 2022.

Millennium Management reported no remaining Theriva Biologics position as of Q2 2022 after selling out during the quarter.
Millennium Management sold 537 Theriva Biologics shares in Q2 2022, an estimated $38K.
Millennium Management first reported a position in Theriva Biologics in Q1 2015 and held it in 14 quarters.
Millennium Management's Theriva Biologics position peaked at $1.01M in Q3 2017.
30 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.